SK Chemicals said that it has signed a joint sales contract with UCB Korea for the latter's epilepsy treatment Keppra lineup (ingredient name: levetiracetam).Under the accord, UCB Korea will sell to top-tier and some general hospitals, and SK Chemicals will conduct marketing for other general hospit
MSD had expected that its pneumococcal vaccine Vaxneuvance would obtain expanded indication for children and infants by April, but the FDA recently pushed back the review date for the drug.With the possibility of the delay in the expanded indication, MSD may not be able to secure a large share in th
Daewon Pharmaceutical said Monday that the company has launched Escorten, its first proton-pump inhibitor drug.Escoten Tablet is a PPI treatment containing esomeprazole magnesium trihydrate as the main ingredient. The company started developing the drug in 2019, completed phase 1 clinical trials in
Handok said it signed a supply and distribution agreement with Incyte Corp. for pemigatinib, a cholangiocarcinoma-targeted treatment targeting the fibroblast growth factor receptor (FGFR 2), and tafasitamab, a CD19-targeted diffuse large B-cell lymphoma treatment.Under the accord, Handok will be res
Medytox said Friday it has filed a complaint with the U.S. International Trade Commission (ITC) against rival botulinum toxin (BTX) maker Hugel, alleging that the latter developed the treatment using a stolen manufacturing secret."Hugel has developed and produced a BTX product by misappropriating tr
New drug development using artificial intelligence (AI) has become a major trend in the global pharmaceutical industry, but some question the feasibility of such efforts.Industry officials said AI would help save cost and time for drug development and raise the chance of commercialization. Yet, no A
Dong-A ST's antibacterial drug Sivextro achieved sales of about 29 billion won ($23.9 million) in the U.S. last year, according to the 2021 performance data released Tuesday by Nabriva Therapeutics, the exclusive marketer of Sivextro in the U.S.Sivextro accounted for 82 percent of Nabriva's total sa
Oscotec said it signed a technology transfer agreement with Kanaph Therapeutics to acquire the exclusive global license for the latter's KNP-502, an EP2/4 dual inhibitor for treating cancer.Under the accord, Kanaph will receive a down payment of 2 billion won ($1.6 million), various milestones and r
As Roche’s Gavreto (pralsetinib) won the regulatory nod following Lilly’s Retevmo (selpercatinib) in March, the two RET (rearranged during transfection) targeted therapies are likely to compete in the Korean market.However, for the two treatments to be used for cancer patients regardless of cancer t
BMS Korea said that Revlimid (ingredient: lenalidomide), its multiple myeloma treatment, will receive insurance benefits as a combination therapy with Velcade (Ingredient: bortezomib) and dexamethasone for treating newly diagnosed multiple myeloma patients from the next month.The Ministry of Health
Curome Bioscience, a Korean bio venture, said that it received orphan drug designation (ODD) for HK-660S, a nicotinamide adenine dinucleotide (NAD+) accelerator, from the U.S. Food and Drug Administration for treating primary sclerosing cholangitis (PSC).HK-660S is undergoing phase 2 in Korea with 2
Roche Korea and the government failed to reach an agreement over the reimbursement rate of Tecentriq (atezolizumab) for the treatment of hepatocellular carcinoma (HCC) within the negotiation deadline.Roche Korea said it was actively talking with the government to win health insurance benefits, but K
Dx&Vx signed a memorandum of understanding on industry-university-research cooperation with the Hanyang Institute of Bioscience and Biotechnology (HY-IBB) on Tuesday.Under the accord, Dx&Vx and HY-IBB will jointly operate NGS (Next Generation Sequencing) equipment of the genome core and collaborate
Menarini Korea plans to introduce a new gel-type erectile dysfunction treatment in Korea.According to the industry sources on Tuesday, Futura Medical, a U.K.-based pharmaceutical company, signed an exclusive license agreement with Menarini Korea for commercializing MED3000, a gel-type erectile dysfu
Three Korean pharmaceutical companies are speeding up U.S. clinical trials to develop a new non-alcoholic steatohepatitis (NASH) treatment.NASH develops when liver tissues have inflammation due to fat accumulated in the liver regardless of alcohol intake. The disease can worsen to become cirrhosis a
Eli Lilly is gearing up to overcome atopic dermatitis (AD) with a new biologic lebrikizumab after releasing an oral JAK inhibitor Olumiant (baricitinib).The company unveiled the results of phase 3 studies of lebrikizumab, an IL-13 inhibitor, at the 2022 American Academy of Dermatology Annual Meeting
Sandoz Korea said that it signed an exclusive sales partnership with Ilsung Pharmaceutical for the latter to market Sandoz Sugammadex Sodium Inj., a neuromuscular agent.Under the accord, Sandoz and Ilsung will supply and sell Sandoz Sugammadex Sodium Inj. to all large and general hospitals from Apri
Eli Lilly’s Janus kinase (JAK) inhibitor Olumiant (baricitinib), which recently came under safety scrutiny, demonstrated therapeutic effects on alopecia areata (AA), a study showed.On Saturday, the New England Journal of Medicine published the results of two phase 3 studies of Olumiant BRAVE-AA1 and
Roche said it confirmed the long-term efficacy and safety profile of Evrysdi (risdiplam), a treatment for spinal muscular atrophy (SMA), in a broad population of people with SMA.As the Health Insurance Review and Assessment Service (HIRA) has been reviewing reimbursement for Evrysdi for eight months
Hanmi Pharmaceutical said it would release Esomezole Plus Tab. 40/350mg, a gastroesophageal reflux disease (GORD) treatment that combined esomeprazole with magnesium hydroxide, an antacid.With the new product, Hanmi has established three types of esomeprazole – Esomezole Cap., Esomezole DR SR Cap.,